Oral administration of ovalbumin protects mice from concanavalin A-induced hepatitis through suppression of interferon-gamma responses.
Hepatitis
Interferon-gamma
Interleukin-4
Oral tolerance
Journal
Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516
Informations de publication
Date de publication:
24 09 2023
24 09 2023
Historique:
received:
27
06
2023
accepted:
29
06
2023
medline:
15
8
2023
pubmed:
8
7
2023
entrez:
7
7
2023
Statut:
ppublish
Résumé
The liver is a tolerogenic organ that exhibits hypo-responsiveness to antigens circulating in the portal vein. Antigens that are orally administered at high doses reach the liver. In our previous study, we demonstrated that administering ovalbumin (OVA) orally at high doses generates unique CD4
Identifiants
pubmed: 37419032
pii: S0006-291X(23)00846-X
doi: 10.1016/j.bbrc.2023.06.091
pii:
doi:
Substances chimiques
Interferon-gamma
82115-62-6
Ovalbumin
9006-59-1
Concanavalin A
11028-71-0
Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-123Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.